Abstract:Background: Type 2 diabetes mellitus (T2DM) has emerged as a global epidemic issue, with high rates of disability and fatality. Traditional diagnostic biomarkers are typically detected once a metabolic imbalance has already occurred, thus the development of early diagnostic biomarkers is crucial for T2DM. Metabolomics studies have identified several predictive biomarkers for T2DM, including miR‐320. Our previous research found that miR‐320b was significantly downregulated in T2DM patients, but the underlying mechanism remains unclear. Therefore, this study was designed to investigate the significance of miR‐320b for T2DM diagnosis and to explore the involved molecular mechanism. Methods: A total of 50 patients with T2DM and 80 sex‐ and age‐matched healthy subjects were selected. The plasma miR‐320b of all participations was detected by qRT‐PCR and its correlations with other biomarkers of T2DM were analyzed. Besides, the expression of miR‐320b in HepG2 cells was suppressed by miRNA inhibitors. Then the glucose consumption of HepG2 cells was measured. The target gene of miR‐320b was predicted by four bioinformatics tools and intersected these prediction results by Venny method. The T2DM relevant target genes were identified by the GeneCards database. To ensure disease relevance, these T2DM relevant target genes were subsequently intersected with the target genes of miR‐320b. Protein–protein analysis (PPI) was used to screening the gene with the most connections in these target genes. Finally, the target gene of miR‐320b specific to T2DM was confirmed directly by luciferase reporter assay. The expression of target gene in HepG2 cell culture supernatant and plasma of all participations was detected. Results: Our results showed that the expression level of miR‐320b was significantly lower in T2DM patients compared to the healthy controls. It was negatively correlated with fasting plasma glucose (FPG), glycated hemoglobin (HbA1C), and homeostasis model assessment of insulin resistance (HOMA‐IR), but positively with HOMA‐β. The glucose consumption of HepG2 cells in the miR‐320b inhibitor group was significantly lower compared to inhibitor‐NC and blank control group. We predicted and confirmed that phosphatase and tensin homolog (PTEN) was the direct target gene of miR‐320b using Bioinformation tools and luciferase reporter assay. Moreover, the concentration of PTEN was significantly higher in the HepG2 cell culture supernatant and plasma of T2DM patients. Conclusions: Our research demonstrated a negative correlation between miR‐320b and FPG, HbA1C, and HOMA‐IR, while exhibiting a positive correlation with HOMA‐β. Suppressing miR‐320b expression would impair glucose consumption of HepG2 cells through PI3K pathway by targeting PTEN. These results suggest that miR‐320b may be a potential biomarker for diagnosing T2DM and a promising target for therapeutic intervention.

Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes

Circulating miR-103 family as potential biomarkers for type 2 diabetes through targeting CAV-1 and SFRP4

Expression level, clinical significance and target gene functions of circu-lating miR-103b in patients with pre-diabetes mellitus

Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke

Abstract P124: Human Small Artery MicroRNA Expression Profiles: Changes in Type 2 Diabetes and Associations with Endothelial Function

Hyperglycaemia-induced reciprocal changes in miR-30c and PAI-1 expression in platelets

miR‐320b, a Future Expected New Biomarker for Type 2 Diabetes Mellitus Induces Dysglycemia by Targeting PTEN

Biomarkers Associated with Ischemic Stroke in Diabetes Mellitus Patients.

Circulating Mir-30C As a Predictive Biomarker of Type 2 Diabetes Mellitus with Coronary Heart Disease by Regulating PAI-1/VN Interactions.

Circulating mir-199-3p screens the onset of type 2 diabetes mellitus and the complication of coronary heart disease and predicts the occurrence of major adverse cardiovascular events

Increased MicroRNA-146a Levels in Plasma of Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus

Expression profiles and bioinformatic analysis of microRNAs in myocardium of diabetic cardiomyopathy mice

MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling

Role of Decreased Expression of Mir-155 and Mir-146A in Peripheral Blood of Type 2 Diabetes Mellitus Patients with Diabetic Peripheral Neuropathy

Differential Expression of Micrornas in Plasma of Patients with Prediabetes and Newly Diagnosed Type 2 Diabetes

Circulating Mir-126 is a Potential Biomarker to Predict the Onset of Type 2 Diabetes Mellitus in Susceptible Individuals.

Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study

Circulating Microrna-194 Levels in Chinese Patients with Diabetic Kidney Disease: a Case–control Study

Two Novel MicroRNA Biomarkers Related to Β-Cell Damage and Their Potential Values for Early Diagnosis of Type 1 Diabetes

Serum Mir-23A, a Potential Biomarker for Diagnosis of Pre-Diabetes and Type 2 Diabetes